Skip to content

Alfentanil as an adjuvant for propofol, ciprofol, and remazolam-based hysteroscopic sedation

Alfentanil as an adjuvant for propofol, ciprofol, and remazolam-based hysteroscopic sedation: a prospective, randomized, controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067310
Enrollment
Unknown
Registered
2023-01-04
Start date
2023-01-12
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstetrics & Gynecology

Interventions

Group 2:Remimazolam intravenous injection
Group 3:Propofol intravenous injection

Sponsors

Department of Anesthesia Surgery, Gansu Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 18 >= age >= 65 years old, female; 2. The ASA score is grade I or grade II; there is no obvious potential difficult airway (the modified Martens score is grade I~III); SpO2 should be >= 92% when inhaling air; 3. BMI is 18 kg/m2 < BMI < 30 kg/m2; 4. Patients who undergo painless hysteroscopy and actively request intravenous anesthesia; 5. The vital signs are within the scope of the protocol requirements, and there are no contraindications for sedation/general anesthesia; 6. There is no primary disease of important organs in the past.

Exclusion criteria

Exclusion criteria: 1. Requires complex endoscopic diagnosis and treatment techniques; 2. Patients who are judged as patients with difficulty in airway management and plan to undergo endotracheal intubation; 3. Those who are allergic or contraindicated to benzodiazepines, opioids, propofol, propofol emulsion injection excipients; 4. Participated in other drug clinical trials as subjects in the past 3 months; 5. The investigator thinks that it is not suitable to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Incidence of intraoperative adverse events;Duration of patient's full consciousness;

Secondary

MeasureTime frame
Injection pain;Satisfaction of gynecologists;

Countries

China

Contacts

Public ContactYan Wenjun

Gansu Provincial People's Hospital

871523533@qq.com+86 138 9337 0700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026